Format

Send to

Choose Destination
Nat Mater. 2019 May 27. doi: 10.1038/s41563-019-0385-5. [Epub ahead of print]

Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations.

Author information

1
Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
2
Department of Pathology, University of Washington, Seattle, WA, USA.
3
Department of Medicine, University of Washington, Seattle, WA, USA.
4
Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. jadair@fredhutch.org.
5
Department of Medicine, University of Washington, Seattle, WA, USA. jadair@fredhutch.org.

Abstract

Ex vivo CRISPR gene editing in haematopoietic stem and progenitor cells has opened potential treatment modalities for numerous diseases. The current process uses electroporation, sometimes followed by virus transduction. While this complex manipulation has resulted in high levels of gene editing at some genetic loci, cellular toxicity was observed. We have developed a CRISPR nanoformulation based on colloidal gold nanoparticles with a unique loading design capable of cellular entry without the need for electroporation or viruses. This highly monodispersed nanoformulation avoids lysosomal entrapment and localizes to the nucleus in primary human blood progenitors without toxicity. Nanoformulation-mediated gene editing is efficient and sustained with different CRISPR nucleases at multiple loci of therapeutic interest. The engraftment kinetics of nanoformulation-treated primary cells in humanized mice are better relative to those of non-treated cells, with no differences in differentiation. Here we demonstrate non-toxic delivery of the entire CRISPR payload into primary human blood progenitors.

PMID:
31133730
DOI:
10.1038/s41563-019-0385-5

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center